首页> 外文期刊>Progress in transplantation: official publication, North American Transplant Coordinators Organization ... [et al.] >Impact of a Clinical Solid Organ Transplant Pharmacist on Tacrolimus Nephrotoxicity, Therapeutic Drug Monitoring, and Institutional Revenue Generation in Adult Kidney Transplant Recipients
【24h】

Impact of a Clinical Solid Organ Transplant Pharmacist on Tacrolimus Nephrotoxicity, Therapeutic Drug Monitoring, and Institutional Revenue Generation in Adult Kidney Transplant Recipients

机译:临床固体器官移植药剂师对成人肾脏移植接受者他克莫司肾毒性,治疗药物监测和机构收益的影响

获取原文
获取原文并翻译 | 示例
       

摘要

Context: Tacrolimus requires close therapeutic drug monitoring (TDM) to ensure efficacy and minimize adverse effects. Pharmacists are uniquely positioned on transplant teams to interpret levels and recommend therapy modifications. Their impact in the immediate postoperative setting has not been described previously. Objective: To evaluate the impact of a clinical solid organ transplant pharmacist on nephrotoxicity, TDM, and revenue generation in adult kidney transplant recipients on tacrolimus. Design, Setting, and Patients: Retrospective assessment of adult kidney transplant recipients at University of Florida Health Shands Hospital. Intervention: A transplant pharmacist rounded 5 days a week and made medication recommendations on transplant recipients-including tacrolimus dose modifications based on levels. Pharmacy services were expanded to include medication reconciliation, medication counseling, and delivery of discharge medications to bedside. Main Outcome Measure: Incidence of nephrotoxicity during tacrolimus exposure. Results: Of the 70 kidney transplant recipients in the postpharmacist cohort, 18 (25.7%) experienced nephrotoxicity while on tacrolimus, compared to 18 (25%) of the 72 in the prepharmacist cohort (P = .922). A significantly greater proportion of recipients who experienced nephrotoxicity were male, had hypertension, or experienced delayed or slow graft function. The rate of appropriately drawn tacrolimus troughs significantly increased from 23.4% to 30.3% in the postpharmacist cohort (P < .001). The median outpatient pharmacy revenue generated per recipient significantly increased from US$345.49 (interquartile range [IQR]: 0-4727.56) to US$4834.95 per recipient (IQR: 3592.78-6224.60; P < .001). The length of stay (7 days, IQR: 6-9, vs 8 days, IQR: 6-9; P = .107) and the 30-day readmission rate were similar between groups (20.8% vs 21.4%; P = .931).
机译:背景:他克莫司需要密切的治疗药物监测(TDM),以确保疗效并最大程度地减少不良反应。药剂师在移植团队中具有独特的地位,可以解释其水平并推荐治疗方案。先前没有描述过它们对术后即时环境的影响。目的:评估临床实体器官移植药剂师对他克莫司成年肾移植受者肾毒性,TDM和创收的影响。设计,环境和患者:佛罗里达大学健康商学院医院对成年肾移植受者的回顾性评估。干预措施:一位移植药剂师每周进行5天巡视,并针对移植接受者提出用药建议-包括根据水平调整他克莫司的剂量。药房服务已扩展到包括药检,药咨询和出院药到床边的运送。主要观察指标:他克莫司暴露期间发生肾毒性的发生率。结果:在药房后队列的70名肾脏移植受者中,有18(25.7%)位在他克莫司时发生肾毒性,而在药房前队列的72位接受者中有18(25%)(P = .922)。发生肾毒性的接受者中,男性,患有高血压或移植物功能延迟或缓慢的比例更大。在药房后队列中,适当绘制的他克莫司谷剂的比率从23.4%显着增加到30.3%(P <.001)。每个接收者产生的门诊药房收入中位数从345.49美元(四分位间距[IQR]:0-4727.56)显着提高到每个接收者4834.95美元(IQR:3592.78-6224.60; P <.001)。两组的住院时间(7天,IQR:6-9,8天,IQR:6-9; P = .107)和30天再入院率相似(20.8%vs 21.4%; P =。 931)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号